Natco Pharma, the Hyderabad-based pharma company has launched Albupax, a nanotechnology drug for treatment of breast cancer.
Over a lakh new incidences of breast cancer are reported in India every year.
Albupax has been indigenously developed by Natco in India. The company has priced each 100 milligram (mg) vial of the drug at Rs 11,500. The estimated domestic market for this product is around Rs 150 crore.
Natco is also planning a tie-up with other companies to introduce the drug in international market.
